Biotechnology
/
Eastern Norway

Radiumhospitalets Forskningsstiftelse
DEVELOPMENT OF CANCER THERAPHY & DIAGNOSTICS

Africa
Asia
Denmark
Europe
North America
Oceania
South America
South Asia
Sweden
West Asia
  • Finance
    Total revenue: 6.878
    Operating profit: -14.556
    Operating profit before tax: 21.807
    Total assets: 281.934
    Total equity: 221.542
    Currency: NOK (all numbers in thousands)
  • Management
    Board Chairman:
    Atle Brynestad


    Board Members:
    Bente-Lill B Romøren
    Erlend Bremertun Smeland
    Ingar Pettersen
    Inger Sandlie





    General Manager:
    Jonas Einarsson


    Subsidiary companies:
    Largest shareholders:
    N/A
    Health Care, Research and development consultancy services,